Android app on Google Play

Insmed (NSM) Doses First Patient in ARIKACE Phase 2

June 27, 2012 8:02 AM EDT Send to a Friend
Insmed Incorporated (Nasdaq: INSM), announced that the first patient has been dosed in the Company's U.S. phase 2 clinical study of ARIKACEĀ® (liposomal amikacin for inhalation) in patients with non-tuberculous mycobacterial (NTM) lung disease entitled TARGET-NTM (Treatment with ARIKACE to Realize Greater Efficacy Trial).




You May Also Be Interested In


Related Categories

Corporate News, FDA

Add Your Comment